Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
When to Start Secukinumab Treatment in Patients with Axial Spondyloarthropathy: Before or After Anti-TNFα Treatment?
Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007
Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.
Keywords:
Identification of Two Tofacitinib Subpopulations with Different Relative Risk Versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance
Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223715 Epub ahead of print
Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.
Keywords:
Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study
Lancet Rheumatol 2023;5:200–207 doi https://doi.org/10.1016/S2665-9913(23)00034-6
Retrospective cohort study found 15 501 PsO patients in the TriNetX database during January 2014–June 2022 that were prescribed bDMARDS, of which 6.3% developed inflammatory arthritis. 3.5% of all patients in the study specifically developed PsA.
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients with Active Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523
TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.
Keywords:
A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report
Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164
Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects
Malignancy Risk with Tofacitinib versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-Label, Randomised Controlled Oral Surveillance Trial
Ann Rheum Dis. 2023;82(3):331–343 doi: 10.1136/ard-2022-222543
Results from the open-label, randomised controlled ORAL Surveillance trial find increased risk of malignancies with tofacitinib versus TNFi, highlighting the highest incidence in patients with a history of atherosclerotic cardiovascular disease or increasing cardiovascular risk.
Keywords:
Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-responder and Secondary Non-responder of Prior TNF Inhibitor in Ankylosing Spondylitis
Mod Rheumatol. 2023 doi: 10.1093/mr/roac005
This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.
Keywords:
Safety of Guselkumab with and without Prior TNF-α Inhibitor Treatment: Pooled Results Across Four Studies in Patients with Psoriatic Arthritis
J Rheumatol. 2023 jrheum
These results demonstrate that guselkumab was well tolerated in studies continuing for 1 to 2 years among patients with moderate-to-severe PsA regardless of TNFi experience and concomitant MTX use. The objective of this study was to assess pooled safety results from Phase 2/3 studies of guselkumab in TNFi-naïve and experienced PsA patients.
Keywords:
Impact of Cardiovascular Risk Enrichment on Incidence of Major Adverse Cardiovascular Events in the Tofacitinib Rheumatoid Arthritis Clinical Programme
Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-223406 Epub ahead of print
Data suggest that an important difference between P123LTE and ORAL Surveillance was the proportion of patients with a history of atherosclerotic CV disease (ASCVD).
Keywords:
Treatment Persistence of Tumour Necrosis Factors And IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Joint Bone Spine 2022; 89:105416 doi: 10.1016/j.jbspin.2022.105416
In this multi-centric, real-world study, persistence with secukinumab and TNFi were not statistically different for matched populations. The primary outcome of this analysis was drug persistence, calculated as the difference in months between initiation and discontinuation.